Background {#Sec1}
==========

Lung cancer (LC) is a malignant lung tumor characterized by unbounded cell growth in the lung tissues \[[@CR1]\]. It is estimated that there are approximately 4,291,600 new cancer cases in China in 2015, and LC is still the main factor for cancer-associated death \[[@CR2], [@CR3]\]. Currently, LCs are frequently divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and 10--15% of LCs are SCLC \[[@CR4], [@CR5]\]. SCLC, a poorly differentiated and aggressive type of LC, presents an early metastases, fleetly growth rate, and poor prognosis with a lower overall 5-year survival rate \[[@CR6]--[@CR8]\]. However, the molecular determinants of SCLC metastasis are unclear. Thus, it is essential to explore the determinants to prevent SCLC metastasis.

Lymph nodes, the central trafficking hubs for recirculating immune cells, are widely present throughout the body \[[@CR9]\]. Conceivably, tumor cells could migrate into the lymph nodes and rapidly spread to other organs \[[@CR10]\]. Activator protein-1 (AP-1), a transcription factor (TF), regulates the gene expression in response to various stimulus \[[@CR11]\]. It has been reported that the overexpression of AP-1 is related to the lymphatic metastasis of LC \[[@CR12]\]. Intriguingly, the abnormal expression of genes regulated by AP-1 was also involved in the process of lymphatic metastasis. For example, previous studies found that the overexpressions of urokinase type plasminogen activator (u-PA) and u-PA receptor (u-PAR) were correlated with the lymphatic metastasis of LC \[[@CR13], [@CR14]\]. In particular, the overexpression of AP-1 contributes to the overexpressions of u-PA and u-PAR. Recently, other studies demonstrated that cyclooxygenase-2 (COX-2) overexpression is well related to the lymphatic metastasis of LC \[[@CR15], [@CR16]\]. In the promoter regions of COX-2 genes, there is a binding site of AP-1 \[[@CR17]\]. Furthermore, in metastatic lymph nodes, the vascular endothelial growth factor C (VEGF-C) overexpression is closely correlated with the lymph node metastasis of NSCLC \[[@CR18]\]. These all findings revealed that the abnormal expression of TFs or genes were associated with the lymphatic metastasis of LC, especially for the NSCLC. However, yet little is known about the processes of tumor cell migration and lymph node metastasis in SCLC \[[@CR19]\]. Therefore, we aimed to explore some novel differentially expressed genes (DEGs) related to the lymph node metastasis process of SCLC, and the potential mechanism would be elucidated.

The bioinformatics analysis methods were carried out for screening DEGs correlated with the lymph node metastasis process of SCLC. Firstly, the DEGs between the metastasis and cancer groups were screened. Afterwards, Gene Ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for the DEGs were implemented to obtain the potential functions of DEGs. Afterwards, the protein--protein interaction (PPI) network and subnetwork of module were established. Then the regulatory networks based on microRNA (miRNAs), TFs and target DEGs were constructed. Ultimately, the survival analysis for DEGs was performed to obtain the DEGs related to the survival of SCLC.

Materials and methods {#Sec2}
=====================

Microarray data {#Sec3}
---------------

The gene expression profiling GSE40275 was obtained from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) \[[@CR20]\], which included 4 SCLC samples with the lymph node metastasis (metastasis group, GSM990225, 226, 227, 247) and 6 SCLC samples without the lymph node metastasis (cancer group, GSM990214, 215, 216, 217, 218, 246). All samples were collected from the SCLC patients and detected through the GPL15974 Human Exon 1.0 ST Array \[CDF: Brainarray Version 9.0.1, HsEx10stv2_Hs_REFSEQ\] platform.

Data preprocessing and DEGs screening {#Sec4}
-------------------------------------

We downloaded the raw CEL data and used the Oligo package (ver.1.38.0) (<http://bioconductor.org/help/search/index.html?q=oligo/>) \[[@CR21]\] in R language to pre-process all the data by performing background correction, conversion of original data and quartile data normalization. In order to remove the probes that cannot match the gene symbol, probes were annotated by the annotations file. The average value of different probes would serve as the final expression level of gene if different probes were mapped to the same gene symbol. DEGs were screened via the classical Bayesian method provided by limma package (ver. 3.30.13, <http://www.bioconductor.org/packages/2.9/bioc/html/limma.html>) \[[@CR22]\]. The setting of thresholds was p value \< 0.05 and \|log fold change (FC)\| ≥ 1.5.

Functional and pathways enrichment analyses {#Sec5}
-------------------------------------------

GO \[[@CR23]\] and KEGG pathway \[[@CR24]\] analyses for DEGs were implemented utilizing the Database for Annotation, Visualization and Integration Discovery (DAVID) (ver. 6.8, <https://david-d.ncifcrf.gov/>) \[[@CR25]\] tool. The number of enrichment genes (count number) ≥ 2 and p value \< 0.05 were regarded as the thresholds criteria.

PPI network and subnetwork of module analyses {#Sec6}
---------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING) (ver. 10.5, <http://www.string-db.org/>) \[[@CR26]\] database was carried out to analyze the protein--protein interactions of DEGs. The DEGs acted as the input gene set, while the homo sapiens served as species. The PPI score was set as 0.4. Thereafter, the Cytoscape (ver. 3.6.0, <http://www.cytoscape.org/>) software was applied to construct the PPI network. The significant clustering modules were analyzed using Molecular Complex Detection (MCODE) (ver. 1.5.1, <http://apps.cytoscape.org/apps/MCODE>) \[[@CR27]\] plugin. The threshold value was set as score ≥ 5.

MiRNAs-TFs-target regulatory network analyses {#Sec7}
---------------------------------------------

The iRegulon (ver. 1.3, <http://apps.cytoscape.org/apps/iRegulon>) \[[@CR28]\] plugin in Cytoscape was performed to predict and analyze the interaction pairs of TF-target gene in the PPI network. The parameters were set as follows: the minimum identity value among orthologous genes was set as 0.05, and the maximum false discovery rate on motif similarity was set as 0.001. The higher score of Normalized Enrichment Score (NES) in output results presented the more reliable results. The TF-target interaction pairs whose NES \> 4 were selected for further study. Afterwards, the miRNAs-target were predicted on the basis of WebGestal (<http://www.webgestalt.org/option.php>) using the Overrepresentation Enrichment Analysis (ORA) method. The setting of threshold was count number ≥ 2 and p value \< 0.05. Ultimately, the miRNAs-TFs-target regulatory network was constructed utilizing the Cytoscape software.

Survival analysis {#Sec8}
-----------------

GSE29016 gene expression profiling data including 20 SCLC samples and clinical data were obtained from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). The common samples between the SCLC samples and clinical data were screened and removed the samples with survival time less than 1 month. Here, a total of 14 samples were enrolled in the present study.

The sample informations were filtered, and the samples were deleted if the survival time was \< 1 month. The samples corresponding to DEGs were screened. The survival package (ver. 2.41-3) in R language and median grouping method were used to conduct the survival analysis. Finally, DEGs under p value \< 0.05 were selected to generate the survival curve.

Results {#Sec9}
=======

Identification of DEGs {#Sec10}
----------------------

We obtained 330 DEGs between the metastasis and cancer groups, of these, 186 were upregulated and 144 were downregulated. The volcano map and heatmap of DEGs were presented in Fig. [1](#Fig1){ref-type="fig"}. Here, our results presented that the expressions of MET proto-oncogene, receptor tyrosine kinase (MET), glutamate metabotropic receptor 8 (GRM8), cholinergic receptor nicotinic alpha 5 subunit (CHRNA5), and dachshund family transcription factor 1 (DACH1) were reduced in the SCLC patients with lymph node metastasis compared with those patients without lymph node metastasis. Besides, glutathione-disulfide reductase (GSR), human leukocyte antigen complex P5 (HCP5), and achaete-scute family bHLH transcription factor 1 (ASCL1) were upregulated in the SCLC patients with lymph node metastasis.Fig. 1The heatmap and volcano plot of DEGs. **a** The heatmap of DEGs. Green colour corresponds to lowest and red to the highest level of gene expression. By unsupervised clustering, the samples all correctly segregate themselves. **b** Volcano plots for all the genes. The green dots indicate that up- and down-regulated DEGs were significant at p values less than 0.05

Functional and pathways enrichment analyses {#Sec11}
-------------------------------------------

The enriched functions for upregulated DEGs were listed in Table [1](#Tab1){ref-type="table"}a, such as kidney development (GO_BP; p value = 1.89 × 10^−4^), extracellular region (GO_CC; p value = 1.72 × 10^−4^), and calcium ion binding (GO_MF; p value = 2.70 × 10^−4^). The enriched functions for downregulated DEGs were presented in Table [1](#Tab1){ref-type="table"}b, such as nervous system development (GO_BP; p value = 2.57 × 10^−6^), integral component of plasma membrane (GO_CC; p value = 4.14 × 10^−4^), and calcium ion binding (GO_MF; p value = 6.10 × 10^−3^). Here, the upregulated DEGs were not enriched in any pathway. However, downregulated DEGs were attracted to 5 pathways (Table [1](#Tab1){ref-type="table"}c), such as transcriptional misregulation in cancer (pathway; p value = 1.64 × 10^−3^), axon guidance (pathway; p value = 4.07 × 10^−3^), and alcoholism (pathway; p value = 1.29 × 10^−2^). Moreover, a total 6 DEGs were attracted to the pathway of transcriptional misregulation in cancer, such as MET.Table 1Enrichment analyses for DEGsCategoryTermDescriptionP valueGenes(a) GO functional analysis for upregulated DEGs BPGO:0001822Kidney development1.89 × 10^− 4^SULF1, ITGA8, etc BPGO:0043066Negative regulation of apoptotic process4.92 × 10^−3^GCLC, CD38, etc BPGO:0045779Negative regulation of bone resorption5.80 × 10^−3^CALCA, CD38, etc BPGO:0000302Response to reactive oxygen species6.35 × 10^−3^GPX2, GSR, etc BPGO:0038083Peptidyl-tyrosine autophosphorylation6.82 × 10^−3^FRK, LYN, etc BPGO:0009725Response to hormone7.81 × 10^−3^GCLC, LYN, etc BPGO:0045892Negative regulation of transcription, DNA-templated9.56 × 10^−3^CD38, GCLC, etc BPGO:0007169Transmembrane receptor protein tyrosine kinase signaling pathway1.43 × 10^−2^FRK, LYN, etc BPGO:0002250Adaptive immune response1.48 × 10^−2^LYN, LAX1, etc BPGO:0050853B cell receptor signaling pathway1.55 × 10^−2^CD38, LYN, etc CCGO:0005576Extracellular region1.72 × 10^−4^CER1, C3, etc CCGO:0005615Extracellular space5.81 × 10^−3^CER1, SELP, etc CCGO:0048471Perinuclear region of cytoplasm7.73 × 10^−3^SYT4, LYN, etc CCGO:0005886Plasma membrane9.00 × 10^−3^SYT4, CDCP1, etc CCGO:0070062Extracellular exosome1.21 × 10^−2^FRK, TSPAN1, etc CCGO:0031234Extrinsic component of cytoplasmic side of plasma membrane2.85 × 10^−2^FRK, LYN, etc. CCGO:0016942Insulin-like growth factor binding protein complex2.89 × 10^−2^IGF1, IGFBP5 CCGO:0042567Insulin-like growth factor ternary complex3.83 × 10^−2^IGF1, IGFBP5 CCGO:0005604Basement membrane4.16 × 10^−2^MATN2, CCDC80, etc CCGO:0005578Proteinaceous extracellular matrix4.69 × 10^−2^P3H1, OGN, etc MFGO:0005509Calcium ion binding2.70 × 10^−4^ME3, SYT4, etc MFGO:0008201Heparin binding1.08 × 10^−3^OGN, SELP, etc. MFGO:0032403Protein complex binding4.45 × 10^−3^CALCA, FYB, etc MFGO:0004715Non-membrane spanning protein tyrosine kinase activity1.06 × 10^−2^FRK, LYN, etc MFGO:0033040Sour taste receptor activity1.97 × 10^−2^PKD2L1, PKD1L3 MFGO:0004222Metalloendopeptidase activity2.59 × 10^−2^ADAM28, MME, etc MFGO:0016668Oxidoreductase activity, acting on a sulfur group of donors, NAD (P) as acceptor3.90 × 10^−2^GSR, TXNRD1 MFGO:0043208Glycosphingolipid binding3.90 × 10^−2^SELP, LYN MFGO:0008237Metallopeptidase activity4.63 × 10^−2^ADAM28, MME, etc. MFGO:0000988Transcription factor activity, protein binding4.85 × 10^−2^HEY1, SMAD3(b) GO analysis for downregulated DEGs BPGO:0007399Nervous system development2.57 × 10^−6^ZC4H2, PCDHB6, etc BPGO:0007156Homophilic cell adhesion via plasma membrane adhesion molecules4.09 × 10^−6^CDH7, FAT1, etc BPGO:0007268Chemical synaptic transmission1.12 × 10^−4^CBLN1, PCDHB6, etc BPGO:0007155Cell adhesion2.53 × 10^−4^EFNB2, SPOCK1, etc BPGO:0001764Neuron migration1.39 × 10^−3^ASTN1, RELN, etc BPGO:0007411Axon guidance8.18 × 10^−3^NEO1, CDH4, etc BPGO:0007416Synapse assembly1.20 × 10^−2^ADGRL3, PCDHB10, etc BPGO:0051965Positive regulation of synapse assembly1.26 × 10^−2^LRRN3, LRRN1, BPGO:0016339Calcium-dependent cell--cell adhesion via plasma membrane cell adhesion molecules2.00 × 10^−2^PCDHB6, PCDHB11, etc BPGO:0045666Positive regulation of neuron differentiation2.31 × 10^−2^SOX11, MMD, etc CCGO:0005887Integral component of plasma membrane4.14 × 10^−4^GRIK2, MET, etc CCGO:0045211Postsynaptic membrane4.08 × 10^−3^CBLN1, ZC4H2, etc CCGO:0005886Plasma membrane1.17 × 10^−2^GRIK2, FHL1, etc CCGO:0031941Filamentous actin2.05 × 10^−2^MYO6, FSCN1, etc CCGO:0030424Axon2.15 × 10^−2^STMN2, CNR1, etc CCGO:0030425Dendrite3.31 × 10^−2^RELN, GNG3, etc CCGO:0000788Nuclear nucleosome3.93 × 10^−2^HIST1H2BB, HIST1H3C, etc CCGO:0043204Perikaryon4.02 × 10^−2^ASTN1, KCNK1, etc CCGO:0034705Potassium channel complex4.21 × 10^−2^KCNA6, KCNK1 CCGO:0030054Cell junction4.64 × 10^−2^ZC4H2, GRIK2, etc MFGO:0005509Calcium ion binding6.10 × 10^−3^CDH7, DGKB, etc MFGO:0032051Clathrin light chain binding3.60 × 10^−2^NSG1, HMP19 MFGO:0009931Calcium-dependent protein serine/threonine kinase activity5.00 × 10^−2^CAMK4, DCXTermDescriptionCountP valueKey genes(c) KEGG pathway analysis for downregulated DEGs hsa05202Transcriptional misregulation in cancer61.64 × 10^−3^HIST1H3J, EYA1, MET, ETV1, HIST1H3C, MEIS1 hsa04360Axon guidance54.07 × 10^−3^EPHA4, PAK3, EFNB2, MET, DPYSL5 hsa05034Alcoholism51.29 × 10^−2^HIST1H3J, HIST1H2BB, CAMK4, HIST1H3C, GNG3 hsa04723Retrograde endocannabinoid signaling41.53 × 10^−2^SLC32A1, GABRG2, CNR1, GNG3 hsa05322Systemic lupus erythematosus43.20 × 10^−2^HIST1H3J, HIST1H2BB, HIST1H3C, HLA-DQA1DEGs, differentially expressed genes; GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes

PPI network and module analyses {#Sec12}
-------------------------------

There were 178 nodes and 237 interaction pairs in the PPI network (Fig. [2](#Fig2){ref-type="fig"}). Afterwards, one subnetwork module a (score = 5) with 5 nodes and 10 interaction pairs was obtained through the MCODE (score ≥ 5) plugin in Cytoscape software. According to the degree of DEGs in the PPI network, the top 10 DEGs were selected, then the GO-BP analysis for the top 10 DEGs and module a DEGs were implemented. The top 10 DEGs in the PPI network and DEGs in the module a are presented in Table [2](#Tab2){ref-type="table"}. The enriched functions for the DEGs in the PPI network were shown in Table [3](#Tab3){ref-type="table"}, such as homeostatic process (GO_BP; p value = 5.44 × 10^−5^), regulation of phosphorylation (GO_BP; p value = 1.53 × 10^−4^), and regulation of phosphate metabolic process (GO_BP; p value = 1.78 × 10^−4^). Meanwhile, the enriched functions for module a DEGs were listed in Table [3](#Tab3){ref-type="table"}, such as G-protein coupled receptor protein signaling pathway (GO_BP; p value = 2.14 × 10^−3^), cell surface receptor linked signal transduction (GO_BP; p value = 9.26 × 10^−3^), and regulation of inflammatory response (GO_BP; p value = 2.23 × 10^−2^). Here, our results showed that GRM8 was attracted to the G-protein coupled receptor signaling pathway.Fig. 2PPI network and subnetwork module of the DEGs. The orange roundness stands for the upregulated DEGs and the green rhombus stands for the downregulated DEGs. PPI, protein--protein interaction; DEGs, differentially expressed genes Table 2The top 10 DEGs in the PPI network and module aGeneDegreeRegulatePPI HIST1H2BB11Down IGF110Up PRKAR2B9Down GNG39Down GSR8Up LYN8Up MGP8Up CALCA7Up TXNRD17UpModule a GNG39Down C36Up GRM85Down SAA15Up CNR15DownDEGs, differentially expressed genes; PPI, protein--protein interaction Table 3Enrichment analyses for DEGs in the PPI network and subnetwork module aTermDescriptionCountP valueKey genesPPI GO:0042592Homeostatic process65.44 × 10^−5^CALCA, GSR, LYN, IGF1, TXNRD1, GNG3 GO:0042325Regulation of phosphorylation51.53 × 10^−4^CALCA, PRKAR2B, LYN, IGF1, GNG3 GO:0019220Regulation of phosphate metabolic process51.78 × 10^−4^CALCA, PRKAR2B, LYN, IGF1, GNG3 GO:0051174Regulation of phosphorus metabolic process51.78 × 10^−4^CALCA, PRKAR2B, LYN, IGF1, GNG3 GO:0009725Response to hormone stimulus41.47 × 10^−3^PRKAR2B, LYN, MGP, GNG3 GO:0009719Response to endogenous stimulus41.96 × 10^−3^PRKAR2B, LYN, MGP, GNG3 GO:0019725Cellular homeostasis42.92 × 10^−3^CALCA, GSR, TXNRD1, GNG3 GO:0043085Positive regulation of catalytic activity43.99 × 10^−3^CALCA, PRKAR2B, GNG3, CAP1 GO:0001932Regulation of protein amino acid phosphorylation35.52 × 10^−3^PRKAR2B, LYN, IGF1 GO:0044093Positive regulation of molecular function45.58 × 10^−3^CALCA, PRKAR2B, GNG3, CAP1Module a GO:0007186G-protein coupled receptor protein signaling pathway42.14 × 10^−3^C3, GRM8, CNR1, GNG3 GO:0007166Cell surface receptor linked signal transduction49.26 × 10^−3^C3, GRM8, CNR1, GNG3 GO:0050727Regulation of inflammatory response22.23 × 10^−2^C3, SAA1 GO:0002526Acute inflammatory response22.87 × 10^−2^C3, SAA1 GO:0007204Elevation of cytosolic calcium ion concentration23.21 × 10^−2^SAA1, GNG3 GO:0051480Cytosolic calcium ion homeostasis23.44 × 10^−2^SAA1, GNG3 GO:0032101Regulation of response to external stimulus24.62 × 10^−2^C3, SAA1DEGs, differentially expressed genes; PPI, protein--protein interaction

MiRNAs-TFs-target regulatory network analyses {#Sec13}
---------------------------------------------

The miRNAs-TFs-target regulatory network was established with 8 TFs, 10 miRNAs and 187 DEGs through the Cytoscape software (Fig. [3](#Fig3){ref-type="fig"}). MiR-126 was identified in the miRNAs-TFs-target regulatory network. A total of 11 genes were regulated by miR-126 in our study, such as GRM8 and DACH1 (Table [4](#Tab4){ref-type="table"}).Fig. 3The miRNAs-TFs -target regulatory network. The orange roundness presents the upregulated DEGs, and the green rhombus presents the downregulated DEGs. The light blue triangle stands for miRNAs, and the yellow hexagon stands for TFs. miRNA, microRNA; TFs, transcription factors; DEGs, differentially expressed genes Table 4Genes associated with miR-126 in miRNAs-TFs-target regulatory networkmiRNAsGenesmiR-126ZMPSTE24miR-126DACH1miR-126EYA1miR-126RNF152miR-126GRM8miR-126ZNF354CmiR-126MYT1miR-126PCSK2miR-126JPH1miR-126TMEM47miR-126XPR1

Survival analysis {#Sec14}
-----------------

Total 164 DEGs have the corresponding sample information. Hence, the 164 DEGs were used for generating the survival curve. There were 2 DEGs correlated with the survival of SCLC, such as GSR and HCP5 (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4The survival curve for the GSR (**a**) and HCP5 (**b**). The horizontal axis represents the survival time (months), and the vertical axis presents the survival rate. The red curve stands for the group of upregulated gene expression (high expression), and the black curve represents the group of downregulated gene expression (low expression). A p value of \< 0.05 was condidered statistically significant between upregulated and downregulated gene expression. GSR, glutathione-disulfide reductase; HCP5, human leukocyte antigen complex P5

Discussion {#Sec15}
==========

SCLC is a highly malignant cancer, and over 70% of patients with SCLC present with the metastatic disease \[[@CR5]\]. But the molecular determinants of SCLC metastasis are unknown. In the current study, some novel DEGs and miRNA associated with the lymph node metastasis of SCLC were obtained via the comprehensive bioinformatical analyses, such as miR-126, DACH1, GRM8, MET, RSD and HCP5.

In SCLC, more than 95% of patients have a smoking history and their 5-year survival rates are under 2% \[[@CR29]\]. As known, a variety of addictive compound nicotine was contained in tobacco, which begins with the binding of nicotine to the nicotinic acetylcholine receptor (nAChR). In especial, the nAChR gene cluster encoding the α3, α5 and β4 nAChR subunits such as CHRNA5/A3/B4 was differentially expressed in SCLC \[[@CR30]\]. In addition, ASCL1 which is a transcription factor implicated in the pathogenesis of SCLC is overexpressed in SCLC \[[@CR31]\]. Similarly, CHRNA5 and ASCL1 were differentially expressed in SCLC with the metastatic disease. Interestingly, ASCL1 might regulate the expression of the clustered nAChR genes. Therefore, positive control genes have validated that the analysis pipeline is doable.

In general, lymph node metastasis of LC is positively related to lymphangiogenesis \[[@CR32]\]. Currently, there is no direct proofs present that miR-126 is significantly associated with the lymph node metastasis of SCLC. However, Sasahira et al. found that the downregulated miR-126 was correlated with the induction of lymphangiogenesis in the OSCC \[[@CR33]\]. It has been uncovered that miR-126 is downregulated in primary SCLC tumor samples \[[@CR34]\]. In addition, miR-126 has an negative effect on the growth and proliferation of SCLC cells \[[@CR35]\]. Meanwhile, miR-126 is also a crucial regulator for the vessel development \[[@CR36]\]. Here, miR-126 was identified in the miRNAs-TFs-target regulatory network. These findings all indicated that miR-126 is likely to participate in the lymph node metastasis process of SCLC through inducing the lymphangiogenesis.

A total of 11 genes were regulated by miR-126 in our study, such as GRM8 and DACH1. DACH1, implicated in the suppression of tumor growth, is downregulated in human malignancies, such as LC \[[@CR37]\]. It is reported that the LC invasion and tumor growth can be inhibited by DACH1 through suppressing the CXCL5 signaling \[[@CR38]\]. Here, our results presented that DACH1 expression was downregulated in the SCLC patients with lymph node metastasis. Probably, DACH1 decrease inhibits the lymph node metastasis process of SCLC. GRM8, encoded by the GRM8 gene, are a family of G protein-coupled receptors. Here, our results showed that GRM8 was downregulated in the SCLC patients with lymph node metastasis and was attracted to the G-protein coupled receptor signaling pathway. However, the role of GRM8 in the lymph node metastasis process of SCLC remains unclear. Previous studies indicated that signaling pathways controlled by GPCRs facilitate proliferation, cell migration, angiogenesis, and inflammation \[[@CR39]\]. Namely, GPCRs are likely to promote the migration of LC cells into the lymph node. Therefore, we speculated that GRM8 was likely to participate in the lymph node metastasis process of SCLC.

The gene expression programs are controlled by a variety of TFs, and its misregulation result in various diseases \[[@CR40]\]. Briefly, the transcriptional misregulation can cause thousands of diseases. Here, a total of 6 DEGs were attracted to the pathway of transcriptional misregulation in cancer, such as MET. It has been revealed that MET regulates the remodeling and morphogenesis of tissues, and its dysregulation is implied in the oncogenic signaling and metastasis \[[@CR41], [@CR42]\]. Here, MET was regulated in the SCLC patients with lymph node metastasis. Thus, MET dysregulation may participate in the lymph node metastasis process of SCLC through the transcriptional misregulation in cancer pathway.

GSR encoded a member of the class-I pyridine nucleotide-disulfide oxidoreductase family, which played a key role in cellular antioxidant defense. GSR reduced oxidized glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH). Whereas, GSH played complex roles in cancer, including the protective and pathogenic roles \[[@CR43]\]. In a previous study, GSR expression level was significantly increased in tumor tissue from patients with LC \[[@CR44]\]. Although there was no direct proofs to indicate GSR association with the lymph node metastasis process of SCLC, the glioblastoma multiforme patients with high GSR expression showed poor survival \[[@CR45]\]. Similarly, GSR was up-regulated in the patients with lymph node metastasis process of SCLC and displayed a poor survival results. Therefore, we speculated that GSR might have a central role in the lymph node metastasis process of SCLC.

In addition, HCP5 was significantly down-regulated in patients with ovarian cancer \[[@CR46]\]. Similarly, HCP5 was also down-expressed in patients with lung adenocarcinoma. However, Teng et al. reported that HCP5 was up-regulated in glioma tissues as well as in U87 and U251 cells \[[@CR47]\]. In addition, they found that HCP5 regulated the glioma cells malignant proliferation through binding to miR-139 by up-regulating RUNX1. Probably, HCP5 expression was different in various cancers. In the present study, HCP5 was upregulated in the lymph node metastasis process of SCLC. Hence, we speculated that GSR and HCP5 may involve in the lymph node metastasis process of SCLC. However, the predicted results cannot be verified by laboratory data due to the limitation of sample extraction. In further studies, we will confirm the expressions of the above discussed DEGs and miRNA once we collected the sufficient samples.

Conclusion {#Sec16}
==========

In summary, our results suggested that miR-126 and its target gene DACH1 may implicate in the lymph node metastasis process of SCLC. Additionally, GRM8, MET, RSD and HCP5 were implicated in the lymph node metastasis process of SCLC.
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